Your Gift Saves Lives!

Your Support Helps Save Lives

This cutting-edge screening modality has become the preferred method over conventional digital mammography. However, does it actually improve detection and survival rates of life-threatening breast cancers? Our researchers are exploring this question through a large-scale, randomized clinical trial in partnership with MedStar Georgetown University Hospital.

Since 2009, the standard has been for women in their forties to make individualized decisions about when to start screening based on their health history and preferences, starting no later than age 50. However, a new study co-authored by Georgetown Lombardi researcher Jeanne S. Mandelblatt, M.D., shows that beginning breast cancer screening every two years at age 40 could reduce breast cancer mortality by 30%, while minimizing false positives.

At Georgetown Lombardi, we believe diversity in clinical trials is essential for effective cancer treatment. Our commitment to inclusivity ensures that our research benefits all populations, regardless of race, ethnicity, or socioeconomic status. By involving a diverse group of participants, we can better understand how different groups respond to various treatments and tailor our approaches to meet their unique needs.

Georgetown Lombardi Comprehensive Cancer Center is one of only 57 research and treatment facilities nationwide that have qualified as a National Cancer Institute-designated Comprehensive Cancer Center, leading the world in innovative cancer research. However, our groundbreaking studies cannot be fully supported by government funds alone.

With your support, we will achieve the next significant breakthrough in breast cancer treatment and other cancers, offering hope and saving lives in the Washington, DC metro area and beyond.

Stay in the fight to save lives today.